AZN vs PFE

For growth investors, AstraZeneca PLC (AZN) is the stronger pick with 8.

6% revenue growth year-over-year, versus -1. 6% for Pfizer Inc. (PFE). Pfizer Inc. (PFE) offers the better valuation at 19. 4x trailing P/E (8. 9x forward), making it the more compelling value choice. Analysts rate AstraZeneca PLC (AZN) a "Buy" — based on 41 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Pfizer Inc.

(PFE) is the cheapest at 19. 4x versus AstraZeneca PLC at 27. 7x. On forward P/E, Pfizer Inc. is actually cheaper at 8. 9x.

Over the past 5 years, AstraZeneca PLC (AZN) delivered a total return of +86.

4%, compared to -13. 2% for Pfizer Inc. (PFE). Over 10 years, the gap is even starker: AZN returned +283. 6% versus PFE's +30. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Pfizer Inc.

(PFE) is the lower-risk stock at 0. 54β versus AstraZeneca PLC's 0. 67β — meaning AZN is approximately 23% more volatile than PFE relative to the S&P 500. On balance sheet safety, AstraZeneca PLC (AZN) carries a lower debt/equity ratio of 61% versus 78% for Pfizer Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), AstraZeneca PLC (AZN) is pulling ahead at 8.

6% versus -1. 6% for Pfizer Inc. (PFE). On earnings-per-share growth, the picture is similar: AstraZeneca PLC grew EPS 190. 7% year-over-year, compared to -3. 5% for Pfizer Inc.. Over a 3-year CAGR, AZN leads at 9. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

AstraZeneca PLC (AZN) is the more profitable company, earning 17.

5% net margin versus 12. 4% for Pfizer Inc. — meaning it keeps 17. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PFE leads at 24. 7% versus 23. 4% for AZN. At the gross margin level — before operating expenses — AZN leads at 81. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Pfizer Inc.

(PFE) trades at 8. 9x forward P/E versus 17. 6x for AstraZeneca PLC — 8. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for AZN: 16. 4% to $211. 00.

All stocks in this comparison pay dividends.

Pfizer Inc. (PFE) offers the highest yield at 6. 5%, versus 1. 8% for AstraZeneca PLC (AZN).

For long-horizon retirement investors, AstraZeneca PLC (AZN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

67), 1. 8% yield, +283. 6% 10Y return). Both have compounded well over 10 years (AZN: +283. 6%, PFE: +30. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: AZN is a large-cap quality compounder stock; PFE is a mid-cap income-oriented stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.